India’s first New Drug, Synriam, developed by Ranbaxy wins Innovation Award
Gurgaon, July 15, 2013: Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359), India’s largest pharmaceutical company, today announced that it has been conferred with the Innovation Excellence...
View Article4th Ubiquitin Research and Drug Discovery Conference
Date: February 20-21, 2014 Venue: San Diego, CA This premier conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus...
View Article6th Ocular Diseases Drug Discovery Conference
Date: February 20-21, 2014 Venue: San Diego, CA The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for...
View ArticleWhy Is It So Hard To Predict Sales Of New Drugs?
It’s not exactly an industry secret. However, an article by authors from McKinsey confirmed that predicting future sales of a new medicine is notoriously inaccurate. In their article, “Pharmaceutical...
View ArticleActelion wins crucial FDA approval for next-gen lung disease drug Opsumit
Late on Friday the FDA came through with an approval for Actelion’s pulmonary arterial hypertension (PAH) drug Opsumit (macitentan), its next-gen successor to the franchise drug Tracleer. And on Monday...
View ArticleTakeda, Hopkins developing new pancreatic cancer drugs
Research presented at the International Conference on Molecular Targets and Cancer Therapeutics this week in Boston could point the way to new therapies to treat pancreatic cancer. Pancreatic cancer...
View ArticleNext Gen: 8th Improving Bioavailabilty & Formulation Conference February...
Strategies for Ensuring Optimum Solubility and Drug Viability This summit investigates the core challenges to achieving maximum bioavailability in drug candidates as well as novel drug delivery...
View ArticleGilead sweeps FDA panel vote for pioneering hep C drug sofosbuvir
There were no big surprises for Gilead’s ($GILD) $11 billion hepatitis C drug sofosbuvir at today’s FDA panel review. The therapy, which promises to help create an entirely new standard of care for the...
View ArticleStudy: R&D for neglected diseases still negligible
Despite some high-profile commitments from some of the industry’s largest innovators, R&D for some of the world’s most deadly neglected diseases remains underfunded and unimpressive, according to a...
View ArticleAstraZeneca to partner with Evotec in kidney disease
HAMBURG, Germany—Evotec AG and AstraZeneca have signed an agreement to take joint action to combat kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel...
View ArticleAlzheimer’s team tackles a daunting R&D field with a new game plan
Martin Tolar is an old hand when it comes to striking deals for experimental Alzheimer’s drugs. As CEO at CoMentis, he reaped a $100 million cash windfall from a 2008 licensing pact with Astellas on a...
View ArticleFast-acting antidepressant agent discovered
Scientists from the University of Chicago have identified a potential new type of antidepressant therapeutic that selectively blocks a serotonin receptor subtype and provides fast-acting relief in...
View ArticleCompound restores learning, memory loss in mice
Australian Prana Biotechnology has published new data showing that its metal-transporting compound PBT2 reversed memory and learning loss associated with the aging process in elderly mice. The study,...
View ArticleMolecule could treat a wide range of CNS disorders
Scientists at the Cambridge, MA, startup Sage Therapeutics have discovered an innate mechanism that indirectly influences a key receptor linked to a number of neurologic and psychiatric disorders,...
View ArticleTracking 20 Years of Compound-to-Target Output from Literature and Patents
The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more...
View ArticleIngredients of a 2,000-y-old medicine
In archaeology, the discovery of ancient medicines is very rare, as is knowledge of their chemical composition. In this paper are presentd the results combining chemical, mineralogical, and botanical...
View ArticleAncient Medical Texts to Help Drug Development
In 2002, Alain Touwaide came across an article about the discovery, some years before, of a medical kit salvaged from a 2,000-year-old shipwreck off the coast of Tuscany. Divers had brought up a copper...
View ArticleTrio of New York biomedical institutions join forces to accelerate drug...
Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College announced today that they have formed the pioneering Tri-Institutional Therapeutics Discovery...
View ArticleEarly FDA approval for Portola
South San Francisco-based Portola Pharmaceuticals ($PTLA) has nabbed boasting rights to the FDA’s new breakthrough drug designation for andexanet alfa (PRT4445), its Factor Xa inhibitor antidote...
View ArticleMale contraceptive breakthrough
Detailed in the Dec. 2 issue of the Proceedings of the National Academy of Sciences, a team at the Monash Institute of Pharmaceutical Sciences in Australia, in collaboration with researchers from the...
View Article